Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Kymera Therapeutics, Inc.KYMR · Entity 3545 | Chief Medical Officer | March 02, 2026 | March 04, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Kymera Therapeutics, Inc.
Report date March 02, 2026 · Filed March 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 117,134 |
Ending reported balance
After 2026-03-04 transaction · row 8
8 source rows · reconciled sequenceRow 1 · 2026-03-02 · Grant · Acquired 17,650 · Balance 127,642 F1: Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon vesting and settlement. The RSUs shall vest in four equal annual installments following March 2, 2026, subject to the reporting person's continued employment through each vesting date. Row 2 · 2026-03-02 · Sale · Disposed 1,510 · Balance 126,132 F2: Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. Such sales were automatic and not in the discretion of the reporting person. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $87.11 to $88.10, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 3 · 2026-03-02 · Sale · Disposed 1,055 · Balance 125,077 F2: Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. Such sales were automatic and not in the discretion of the reporting person. F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $88.11 to $89.01, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 4 · 2026-03-02 · Sale · Disposed 3,048 · Balance 122,029 F2: Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. Such sales were automatic and not in the discretion of the reporting person. F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $89.17 to $90.12, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 5 · 2026-03-04 · Sale · Disposed 492 · Balance 121,537 F2: Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. Such sales were automatic and not in the discretion of the reporting person. F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $83.36 to $84.3338, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 6 · 2026-03-04 · Sale · Disposed 2,519 · Balance 119,018 F2: Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. Such sales were automatic and not in the discretion of the reporting person. F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $84.4475 to $85.44, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 7 · 2026-03-04 · Sale · Disposed 1,437 · Balance 117,581 F2: Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. Such sales were automatic and not in the discretion of the reporting person. F8: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $85.45 to $86.43, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 8 · 2026-03-04 · Sale · Disposed 447 · Balance 117,134 F2: Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. Such sales were automatic and not in the discretion of the reporting person. F9: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $86.48 to $86.97, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $90.10 · Expires 2036-03-01 | Direct | 35,300 |
Reported balance
After 2026-03-02 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-03-02 · Grant · Acquired 35,300 · Balance 35,300 F10: The shares underlying this stock option shall vest in forty-eight (48) equal monthly installments following March 2, 2026, subject to the reporting person's continued employment through each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon vesting and settlement. The RSUs shall vest in four equal annual installments following March 2, 2026, subject to the reporting person's continued employment through each vesting date.
F2: Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. Such sales were automatic and not in the discretion of the reporting person.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $87.11 to $88.10, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $88.11 to $89.01, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $89.17 to $90.12, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $83.36 to $84.3338, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $84.4475 to $85.44, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F8: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $85.45 to $86.43, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F9: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $86.48 to $86.97, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F10: The shares underlying this stock option shall vest in forty-eight (48) equal monthly installments following March 2, 2026, subject to the reporting person's continued employment through each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 09, 2024 Filed Feb 10, 2024 00:47 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 7,398 | $36.09 | $267,013.05 |
DisclosureSEC source: 0000950170-24-013482 · ownership.xml · nonDerivative · entry 3 Gollob Jared · CIK 0001821198 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 74,709 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 22, 2023 adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.00 to $36.21, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 09, 2024 Filed Feb 10, 2024 00:47 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 38,739 | $35.39 | $1,371,058.44 |
DisclosureSEC source: 0000950170-24-013482 · ownership.xml · nonDerivative · entry 2 Gollob Jared · CIK 0001821198 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 82,107 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 22, 2023 adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.00 to $35.99, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 09, 2024 Filed Feb 10, 2024 00:47 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionCommon Stock | 46,137 | $2.08 | $95,964.96 |
DisclosureSEC source: 0000950170-24-013482 · ownership.xml · nonDerivative · entry 1 Gollob Jared · CIK 0001821198 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 120,846 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 22, 2023 adopted by the reporting person. Read SEC document |
| March 02, 2023 Filed Mar 3, 2023 21:30 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 297 | $31.40 | $9,325.00 |
DisclosureSEC source: 0000899243-23-006981 · doc4.xml · nonDerivative · entry 3 Gollob Jared · CIK 0001821198 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,709 F2 · kind: Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. These sales were automatic and intended to qualify under Rule 10b5-1. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.32 to $31.46, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 02, 2023 Filed Mar 3, 2023 21:30 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 1,001 | $30.88 | $30,908.28 |
DisclosureSEC source: 0000899243-23-006981 · doc4.xml · nonDerivative · entry 2 Gollob Jared · CIK 0001821198 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,006 F2 · kind: Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. These sales were automatic and intended to qualify under Rule 10b5-1. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.30 to $31.25, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 21:30 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | GrantStock Option (Right to Buy) · Derivative | 112,500 | $0.00 Strike: $32.07 | $0.00 |
DisclosureSEC source: 0000899243-23-006981 · doc4.xml · derivative · entry 4 Gollob Jared · CIK 0001821198 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,500 Underlying: Common Stock · 112,500 shares Expires 2033-02-28 F5 · derivative.exercise_date: The shares underlying this stock option shall vest in thirty-six (36) equal monthly installments following March 1, 2023, subject to the reporting person's continued employment through each vesting date. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 21:30 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | GrantCommon Stock | 18,750 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-006981 · doc4.xml · nonDerivative · entry 1 Gollob Jared · CIK 0001821198 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,007 F1 · shares: Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon vesting and settlement. The RSUs shall vest in three equal annual installments following March 1, 2023, subject to the reporting person's continued employment through each vesting date. Read SEC document |
| May 04, 2022 Filed May 4, 2022 13:02 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionStock Option (Right to Buy) · Derivative | 9,792 | $0.00 Strike: $2.08 | $0.00 |
DisclosureSEC source: 0000899243-22-016538 · doc4.xml · derivative · entry 4 Gollob Jared · CIK 0001821198 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,020 Underlying: Common Stock · 9,792 shares Expires 2029-05-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The shares underlying this stock option shall vest in forty-eight (48) equal monthly installments following the vesting commencement date of February 7, 2019, subject to the reporting person's continued employment through each vesting date. Read SEC document |
| May 04, 2022 Filed May 4, 2022 13:02 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,208 | $0.00 Strike: $1.31 | $0.00 |
DisclosureSEC source: 0000899243-22-016538 · doc4.xml · derivative · entry 3 Gollob Jared · CIK 0001821198 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,799 Underlying: Common Stock · 10,208 shares Expires 2028-10-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares underlying this stock option vested on September 12, 2019 and the remaining shall vest in equal monthly installments over the remaining thirty-six (36) months, subject to the reporting person's continued employment through each vesting date. Read SEC document |
| May 04, 2022 Filed May 4, 2022 13:02 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionCommon Stock | 9,792 | $2.08 | $20,367.36 |
DisclosureSEC source: 0000899243-22-016538 · doc4.xml · nonDerivative · entry 2 Gollob Jared · CIK 0001821198 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,257 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 04, 2022 Filed May 4, 2022 13:02 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionCommon Stock | 10,208 | $1.31 | $13,372.48 |
DisclosureSEC source: 0000899243-22-016538 · doc4.xml · nonDerivative · entry 1 Gollob Jared · CIK 0001821198 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,465 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 21:30 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | GrantStock Option (Right to Buy) · Derivative | 75,800 | $0.00 Strike: $38.53 | $0.00 |
DisclosureSEC source: 0000899243-22-009076 · doc4.xml · derivative · entry 2 Gollob Jared · CIK 0001821198 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,800 Underlying: Common Stock · 75,800 shares Expires 2032-02-29 F2 · derivative.exercise_date: The shares underlying this stock option shall vest in thirty-six (36) equal monthly installments following March 1, 2022, subject to the reporting person's continued employment through each vesting date. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 21:30 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | GrantCommon Stock | 12,600 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-009076 · doc4.xml · nonDerivative · entry 1 Gollob Jared · CIK 0001821198 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,257 F1 · shares: Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon vesting and settlement. The RSUs shall vest in three equal annual installments following March 1, 2022, subject to the reporting person's continued employment through each vesting date. Read SEC document |
| November 02, 2021 Filed Nov 2, 2021 22:45 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionStock Option (Right to Buy) · Derivative | 14,996 | $0.00 Strike: $2.08 | $0.00 |
DisclosureSEC source: 0000899243-21-042437 · doc4.xml · derivative · entry 13 Gollob Jared · CIK 0001821198 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,812 Underlying: Common Stock · 14,996 shares Expires 2029-05-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · derivative.exercise_date: The shares underlying this stock option shall vest in forty-eight (48) equal monthly installments following the vesting commencement date of February 7, 2019, subject to the reporting person's continued employment through each vesting date. Read SEC document |
| November 02, 2021 Filed Nov 2, 2021 22:45 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 1,202 | $64.34 | $77,333.19 |
DisclosureSEC source: 0000899243-21-042437 · doc4.xml · nonDerivative · entry 10 Gollob Jared · CIK 0001821198 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,657 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020. F8 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $64.13 to $64.48. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| November 02, 2021 Filed Nov 2, 2021 22:45 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 5,280 | $63.50 | $335,287.39 |
DisclosureSEC source: 0000899243-21-042437 · doc4.xml · nonDerivative · entry 9 Gollob Jared · CIK 0001821198 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,859 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020. F7 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $63.13 to $64.09. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| November 02, 2021 Filed Nov 2, 2021 22:45 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 8,514 | $62.89 | $535,442.05 |
DisclosureSEC source: 0000899243-21-042437 · doc4.xml · nonDerivative · entry 8 Gollob Jared · CIK 0001821198 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,139 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020. F6 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $62.13 to $63.12. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| November 02, 2021 Filed Nov 2, 2021 22:45 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionCommon Stock | 14,996 | $2.08 | $31,191.68 |
DisclosureSEC source: 0000899243-21-042437 · doc4.xml · nonDerivative · entry 7 Gollob Jared · CIK 0001821198 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,653 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 01, 2021 Filed Nov 2, 2021 22:45 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,607 | $0.00 Strike: $2.08 | $0.00 |
DisclosureSEC source: 0000899243-21-042437 · doc4.xml · derivative · entry 12 Gollob Jared · CIK 0001821198 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,808 Underlying: Common Stock · 4,607 shares Expires 2029-05-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · derivative.exercise_date: The shares underlying this stock option shall vest in forty-eight (48) equal monthly installments following the vesting commencement date of February 7, 2019, subject to the reporting person's continued employment through each vesting date. Read SEC document |
| November 01, 2021 Filed Nov 2, 2021 22:45 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $1.31 | $0.00 |
DisclosureSEC source: 0000899243-21-042437 · doc4.xml · derivative · entry 11 Gollob Jared · CIK 0001821198 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,007 Underlying: Common Stock · 20,000 shares Expires 2028-10-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: Twenty-five percent (25%) of the shares underlying this stock option vested on September 12, 2019 and the remaining shall vest in equal monthly installments over the remaining thirty-six (36) months, subject to the reporting person's continued employment through each vesting date. Read SEC document |
| November 01, 2021 Filed Nov 2, 2021 22:45 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 4,065 | $63.17 | $256,798.65 |
DisclosureSEC source: 0000899243-21-042437 · doc4.xml · nonDerivative · entry 6 Gollob Jared · CIK 0001821198 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,657 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020. F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $63.03 to $63.57. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| November 01, 2021 Filed Nov 2, 2021 22:45 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 15,911 | $62.34 | $991,945.84 |
DisclosureSEC source: 0000899243-21-042437 · doc4.xml · nonDerivative · entry 5 Gollob Jared · CIK 0001821198 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,722 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $62.03 to $63.01. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| November 01, 2021 Filed Nov 2, 2021 22:45 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 15,134 | $61.50 | $930,709.22 |
DisclosureSEC source: 0000899243-21-042437 · doc4.xml · nonDerivative · entry 4 Gollob Jared · CIK 0001821198 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,633 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $61.01 to $62.00. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| November 01, 2021 Filed Nov 2, 2021 22:45 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 7,387 | $60.40 | $446,141.56 |
DisclosureSEC source: 0000899243-21-042437 · doc4.xml · nonDerivative · entry 3 Gollob Jared · CIK 0001821198 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,767 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $60.00 to $60.98. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| November 01, 2021 Filed Nov 2, 2021 22:45 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionCommon Stock | 4,607 | $2.08 | $9,582.56 |
DisclosureSEC source: 0000899243-21-042437 · doc4.xml · nonDerivative · entry 2 Gollob Jared · CIK 0001821198 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,154 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 01, 2021 Filed Nov 2, 2021 22:45 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionCommon Stock | 20,000 | $1.31 | $26,200.00 |
DisclosureSEC source: 0000899243-21-042437 · doc4.xml · nonDerivative · entry 1 Gollob Jared · CIK 0001821198 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,547 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 15, 2021 Filed Mar 16, 2021 01:12 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,800 | $0.00 Strike: $1.31 | $0.00 |
DisclosureSEC source: 0000899243-21-011749 · doc4.xml · derivative · entry 6 Gollob Jared · CIK 0001821198 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,007 Underlying: Common Stock · 7,800 shares Expires 2028-10-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Twenty-five percent (25%) of the shares underlying this stock option vested on September 12, 2019 and the remaining shall vest in equal monthly installments over the remaining thirty-six (36) months, subject to the reporting person's continued employment through each vesting date. Read SEC document |
| March 15, 2021 Filed Mar 16, 2021 01:12 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 10,305 | $60.17 | $620,051.85 |
DisclosureSEC source: 0000899243-21-011749 · doc4.xml · nonDerivative · entry 4 Gollob Jared · CIK 0001821198 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,547 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $60.00 to $60.85. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| March 15, 2021 Filed Mar 16, 2021 01:12 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionCommon Stock | 7,800 | $1.31 | $10,218.00 |
DisclosureSEC source: 0000899243-21-011749 · doc4.xml · nonDerivative · entry 3 Gollob Jared · CIK 0001821198 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,852 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 11, 2021 Filed Mar 16, 2021 01:12 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,200 | $0.00 Strike: $1.31 | $0.00 |
DisclosureSEC source: 0000899243-21-011749 · doc4.xml · derivative · entry 5 Gollob Jared · CIK 0001821198 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,807 Underlying: Common Stock · 2,200 shares Expires 2028-10-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Twenty-five percent (25%) of the shares underlying this stock option vested on September 12, 2019 and the remaining shall vest in equal monthly installments over the remaining thirty-six (36) months, subject to the reporting person's continued employment through each vesting date. Read SEC document |
| March 11, 2021 Filed Mar 16, 2021 01:12 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 4,695 | $60.05 | $281,938.98 |
DisclosureSEC source: 0000899243-21-011749 · doc4.xml · nonDerivative · entry 2 Gollob Jared · CIK 0001821198 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,052 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $60.00 to $60.385. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| March 11, 2021 Filed Mar 16, 2021 01:12 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionCommon Stock | 2,200 | $1.31 | $2,882.00 |
DisclosureSEC source: 0000899243-21-011749 · doc4.xml · nonDerivative · entry 1 Gollob Jared · CIK 0001821198 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,747 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 21:57 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $48.46 | $0.00 |
DisclosureSEC source: 0000899243-21-009416 · doc4.xml · derivative · entry 1 Gollob Jared · CIK 0001821198 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2031-02-28 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in thirty-six (36) equal monthly installments over three (3) years following the Grant Date, with the first installment vesting on April 1, 2021. Read SEC document |
| February 24, 2021 Filed Feb 24, 2021 23:44 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 8,675 | $50.91 | $441,671.14 |
DisclosureSEC source: 0000899243-21-008085 · doc4.xml · nonDerivative · entry 3 Gollob Jared · CIK 0001821198 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,547 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020. Read SEC document |
| February 23, 2021 Filed Feb 24, 2021 23:44 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 19,285 | $49.65 | $957,554.25 |
DisclosureSEC source: 0000899243-21-008085 · doc4.xml · nonDerivative · entry 2 Gollob Jared · CIK 0001821198 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,222 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020. Read SEC document |
| February 22, 2021 Filed Feb 24, 2021 23:44 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 9,104 | $52.63 | $479,129.86 |
DisclosureSEC source: 0000899243-21-008085 · doc4.xml · nonDerivative · entry 1 Gollob Jared · CIK 0001821198 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,507 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020. Read SEC document |
| February 19, 2021 Filed Feb 20, 2021 00:27 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 8,887 | $55.09 | $489,559.06 |
DisclosureSEC source: 0000899243-21-007455 · doc4.xml · nonDerivative · entry 3 Gollob Jared · CIK 0001821198 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,611 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020. Read SEC document |
| February 18, 2021 Filed Feb 20, 2021 00:27 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 6,499 | $55.94 | $363,540.41 |
DisclosureSEC source: 0000899243-21-007455 · doc4.xml · nonDerivative · entry 2 Gollob Jared · CIK 0001821198 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,498 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020. Read SEC document |
| February 17, 2021 Filed Feb 20, 2021 00:27 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 7,550 | $58.39 | $440,836.20 |
DisclosureSEC source: 0000899243-21-007455 · doc4.xml · nonDerivative · entry 1 Gollob Jared · CIK 0001821198 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,997 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020. Read SEC document |
| August 20, 2020 Filed Aug 21, 2020 22:31 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | GrantStock Option (Right to Buy) · Derivative | 48,942 | $0.00 Strike: $20.00 | $0.00 |
DisclosureSEC source: 0000899243-20-023247 · doc4.xml · derivative · entry 1 Gollob Jared · CIK 0001821198 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,942 Underlying: Common Stock · 48,942 shares Expires 2030-08-19 F1 · derivative.exercise_date: The shares subject to this option shall vest in forty-eight (48) equal monthly installments over four (4) years commencing on the date of the Registration Statement Effectiveness. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.